clinical-trials
60 stories related to this topic, newest first.
Nbc NewsPersonalized mRNA Vaccine Shows Reduced Melanoma Recurrence in Small Phase 2 Trial
A Moderna and Merck experimental vaccine cut melanoma recurrence risk by half in a five-year trial. Results were presented June 1, 2026, at the American Society of Clinical Oncology meeting.
manilatimes.netVor Bio Awards Stock Options, RSUs to 10 New Hires as Inducements
The Compensation Committee approved equity awards covering 73,950 shares under the 2023 Inducement Plan on June 1, 2026. The grants comply with Nasdaq Listing Rule 5635(c)(4).
news24.comPROTEUS Phase 3 Trial Finds Adding Second Perioperative Hormone Therapy to Prostatectomy Reduced Recurrence Risk in High-Risk Localized
A Phase 3 study found combining two hormone therapies before and after prostate removal produced better results than one hormone therapy in high-risk, early-stage cases. The findings may establish a third treatment path alongside surgery alone or radiation with hormone therapy.
New ScientistPhase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic Cancer
A 500-person study found the once-daily pill halted or reversed tumor progression in nearly one-third of patients versus 10 percent on chemotherapy. Median survival rose from less than seven months to roughly 13 months.
StatRevolution Medicines Reports Pancreatic Cancer Drug Data at ASCO
New results for Revolution Medicines' daraxonrasib were presented at the ASCO conference over the weekend. A pancreatic cancer expert described an emotional reaction after treating patients with the data.
livemint.comEli Lilly Tests One-Time Gene-Editing Infusion for High Cholesterol
Eli Lilly is conducting early trials of VERVE-102, a gene-editing therapy designed to lower LDL cholesterol after a single four-hour infusion. An initial study of 35 participants showed LDL reductions of up to 62 percent, with effects lasting up to 18 months in more than one-thir…
citizen.co.zaExperimental Lung Cancer Drug Cuts Death Risk by 34% in China Trial
An ivonescimab-based therapy from Akeso and Summit Therapeutics lowered death risk by 34% versus standard care in a late-stage Chinese study. Median survival reached 27.9 months compared with 23.7 months for patients on a PD-1 drug plus chemotherapy.
singularityhub.comCancer Shot Eliminated Tumors in 15 of 102 Trial Participants
A clinical trial of an experimental cancer injection showed tumor shrinkage in 43 patients and complete tumor elimination in 15 others. The results come from a study involving 102 participants.
fortune.comDrug Doubles Survival in Metastatic Pancreatic Cancer Trial
An international trial presented Sunday showed daraxonrasib doubled median survival for patients with metastatic pancreatic cancer compared with standard chemotherapy. France has expanded a personalized screening program to eight additional centers.
The TimesResearchers Report Daily Pill Shows Promise in Cancer Treatment Studies
A research team announced results from trials of an oral medication designed to target cancer cells. The findings were presented as a potential advance for patients undergoing treatment.
Science NewsDaraxonrasib Extends Median Survival by Six Months vs Chemotherapy in Previously Treated Advanced Pancreatic Cancer
A Phase III trial of 500 patients found the oral drug daraxonrasib extended median survival to 13 months versus less than seven months with chemotherapy. Results were presented May 31, 2026 at ASCO and published the same day in the New England Journal of Medicine.
Science NewsPill Nearly Doubles Survival Time in Pancreatic Cancer Trial
A once-daily pill nearly doubled average survival for patients with advanced pancreatic cancer in a 500-patient randomized study. Patients on the drug lived 13.2 months on average versus 6.6 months on chemotherapy.
StatIvonescimab Shows 34% Reduction in Death Risk vs. Standard Therapy in China-Only Squamous NSCLC Trial
Data from a China-only trial of ivonescimab were presented May 31, 2026, at the American Society of Clinical Oncology meeting in Chicago and published simultaneously in The Lancet.
Ivonescimab Plus Chemotherapy Extends Median Survival by Four Months vs Tislelizumab in Chinese Lung Cancer Trial
Data released Sunday showed ivonescimab reduced death risk by 34 percent versus a PD-1 drug plus chemotherapy. The results are being presented at the ASCO meeting.
Amivantamab Shows Tumor Response in 43 of 102 Patients With Advanced Head and Neck Cancer
An 11-nation trial of the Johnson & Johnson drug showed tumor shrinkage in more than a third of patients whose disease had returned or spread. Median survival reached 12.5 months after treatment began.
StatBioNTech and Pfizer Present Bispecific Antibody Data at Oncology Meeting
BioNTech and Pfizer presented data on bispecific antibodies at the American Society of Clinical Oncology annual meeting. The companies highlighted results from studies involving new immunotherapies. Coverage also noted comments from an FDA official on agency operations.
The GuardianAmivantamab Shows Tumor Responses in 43 of 102 Patients with Advanced Head and Neck Cancer
An international trial found the Johnson & Johnson drug shrank or eliminated tumors in 43 of 102 patients whose disease had resisted prior chemotherapy and immunotherapy. Results will be presented Sunday at the American Society of Clinical Oncology meeting in Chicago.
The GuardianGalleri Blood Test Shows No Significant Reduction in Advanced Cancers but Cuts Stage 4 Diagnoses by 14% in Large NHS Trial
A multi-cancer early detection blood test did not reduce late-stage diagnoses when added to standard screening. Data were presented at the American Society of Clinical Oncology meeting in Chicago.
/cdn.vox-cdn.com/uploads/chorus_asset/file/24856972/236744_Withings_Body_Smart_VSong_0003.jpg)
theverge.comRetatrutide Shows 28 Percent Body Weight Reduction in Trials
Retatrutide, a triple-receptor drug targeting GLP-1, GIP, and glucagon, produced the largest average weight loss reported so far. The medication also carries additional safety considerations.
foxbusiness.comFDA Rejects Experimental Melanoma Drug Twice Over Study Design
The Food and Drug Administration turned down an experimental melanoma treatment on two separate occasions after raising questions about how the supporting clinical study was structured. The agency cited concerns with the trial's design as the basis for both rejections.
koreaherald.comAptose Biosciences Delays Closing of Hanmi Acquisition to June
Aptose Biosciences said regulatory approvals in South Korea are still pending for its planned acquisition by Hanmi Pharmaceutical. The companies now target closing in June and have received an additional loan advance to continue operations.
foxnews.comGene Therapies Advance to Human Trials for Heart Regeneration
Researchers have begun the first clinical trial of a gene therapy designed to grow new heart-muscle cells. At least four additional regenerative gene therapies for heart conditions are in development by companies.
financialpost.comXPRIZE Healthspan Competition Selects 10 Teams for Aging Research Trials
The $101 million XPRIZE Healthspan program will require selected teams to conduct yearlong randomized controlled trials testing therapies aimed at restoring muscle, cognition, and immune function in older adults. The winner is scheduled to be announced in 2030.
New York PostNew drug achieves functional cure in 20 percent of chronic hepatitis B patients
A clinical trial found that bepirovirsen rendered the hepatitis B virus undetectable in 20 percent of treated patients after 48 weeks. The study enrolled more than 1,838 participants across 29 countries. No patients receiving placebo achieved the same outcome.
The IndependentGSK Hepatitis B Drug Shows Functional Cure in 20 Percent of Trial Patients
Two international studies found that bepirovirsen produced sustained viral suppression in roughly one-fifth of participants after treatment ended. The drug is under FDA fast-track review with a decision expected in October.
StatGSK Drug Achieves Functional Cure in 19-20% of Hepatitis B Patients
Two Phase 3 trials showed GSK's bepirovirsen produced functional cures in nearly one-fifth of chronic hepatitis B patients. Current nucleoside analogue treatments reach functional cures in only 1-3% of cases. The company has submitted the drug for regulatory approval.
prnewswire.comResearchers Report Kilogram-Scale Synthesis of Cholesterol Drug Enlicitide
A Science study describes a new production method for enlicitide, a peptide in Phase 3 trials for lowering LDL cholesterol. The route uses engineered enzymes and crystallization steps to reduce reaction count and raise yield.
foxnews.comCancer Immunotherapy Pipeline Expands With Multiple New Drug Classes
More than 2,500 cancer immunotherapy programs are now active. Fifteen years after the first checkpoint inhibitor approval, several additional drug types have reached FDA approval or late-stage testing.
thehindu.comMerck drug combination reduces lung cancer progression risk in trial
A Merck antibody-drug conjugate combined with Keytruda lowered the risk of tumor progression by 65 percent in a Phase 3 lung cancer study. The results come from an abstract released ahead of the American Society of Clinical Oncology meeting.
bbc.co.ukEnhanced Games Releases Substance Use Data Ahead of Las Vegas Event
Enhanced Games reported substance usage rates from its IRB-approved clinical trial before the first competition scheduled for May 24 at Resorts World Las Vegas. The data showed high percentages of athletes using performance-related substances.
finance.yahoo.comEli Lilly Reports Retatrutide Helped Patients Lose 70 Pounds in Trial
Eli Lilly announced clinical trial results showing its experimental obesity drug retatrutide produced greater weight loss than its existing treatments Zepbound and Wegovy. The company said participants lost an average of 70 pounds over 80 weeks.
manilatimes.netPerspective Therapeutics to Present Clinical Updates at 2026 ASCO Meeting
Perspective Therapeutics announced it will present data from three ongoing cancer treatment studies at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.
StatMerck-Kelun Drug Reduced Lung Cancer Progression Risk by 65 Percent in Trial
Phase 3 study results showed that a targeted chemotherapy developed by Kelun-Biotech and licensed to Merck reduced tumor progression risk by 65 percent in patients with advanced non-small cell lung cancer. A preliminary survival benefit was observed but requires longer follow-up…
neurosciencenews.comStudy Tests Arthritis Drug for Hard-to-Treat Depression
A small clinical trial examined whether tocilizumab, an anti-inflammatory drug used for rheumatoid arthritis, could reduce symptoms in patients who have not responded to standard antidepressants. The University of Bristol study involved 30 participants and found greater improveme…
Nbc NewsEli Lilly Weight Loss Drug Retatrutide Shows Up to 30 Percent Body Weight Loss in Trial
Eli Lilly reported that its experimental drug retatrutide produced average weight loss of 28 percent after 80 weeks and up to 85 pounds in some patients. The results come from a phase 3 trial of roughly 2,300 people and remain comparable to outcomes from bariatric surgery.
benzinga.comEli Lilly Reports Retatrutide Weight Loss Results in Phase 3 Trial
Eli Lilly reported results from a late-stage trial of its obesity drug retatrutide. Patients who stayed on the highest dose lost an average of 28.3 percent of their body weight after 80 weeks.
rnz.co.nzSmall Trial Tests Interleukin-6 Blocker for Depression
A pilot study examined whether an anti-inflammatory drug could reduce symptoms in people with depression. The placebo-controlled randomized trial involved a small number of participants.
ncbi.nlm.nih.govStudy Examines Weight Loss and Atrial Fibrillation Recurrence
A new randomized trial published in JAMA assessed whether weight loss reduces atrial fibrillation recurrence. Results differed based on whether the condition was chronic or recent in onset.
interestingengineering.comStudy Finds Fabricated Data in Up to One Quarter of Clinical Trials
An analysis of randomized controlled trials found that many published studies contain flawed or fabricated data. Researchers warn that these unreliable trials can influence medical guidelines and patient care.
Fox NewsMerck Drug Sac-TMT Meets Survival Goals in Endometrial Cancer Trial
Merck announced Monday that its investigational drug sacituzumab tirumotecan met primary survival endpoints in a Phase 3 trial for advanced or recurrent endometrial cancer. The TroFuse-005 study compared the drug to physician-chosen chemotherapy in 776 patients.
themarketherald.com.auPsilocybin Trial Shows Reduced Cocaine Use in Small Study
A randomized trial of 40 participants found that a single dose of psilocybin produced higher abstinence rates from cocaine compared with placebo after six months. The study tested a treatment approach that had not previously been examined for cocaine addiction.
medpagetoday.comIpsen Reports Head-to-Head Trial Results Comparing Dysport and Botox for Upper Limb Spasticity
Ipsen announced results from a Phase IV trial that compared Dysport and Botox in adults with upper limb spasticity. The study met its primary safety endpoint and a secondary efficacy endpoint showing longer duration of response for Dysport.
The Sydney Morning HeraldAmplia Therapeutics Starts Phase 2b Trial of Narmafotinib for Pancreatic Cancer
Amplia Therapeutics has begun a Phase 2b study testing daily dosing of narmafotinib in newly diagnosed pancreatic cancer patients. The trial combines the drug with standard chemotherapy and will initially enroll 12 patients across Australian sites.
benzinga.comSanofi Reports Phase 2 Results for Efdoralprin Alfa in Alpha-1 Antitrypsin Deficiency
Sanofi announced that its Phase 2 Elevaate study showed efdoralprin alfa normalized and maintained functional AAT levels in patients with alpha-1 antitrypsin deficiency. All key secondary endpoints were met and the treatment was well tolerated.
indiatoday.intoday.inTrial of Experimental Treatments for Ebola Bundibugyo Virus Planned in Africa
The World Health Organization declared an Ebola outbreak in the Democratic Republic of the Congo a public health emergency of international concern on 17 May. Scientists are preparing a clinical trial of two experimental therapies against the rare Ebola Bundibugyo virus.
benzinga.comQuince Therapeutics Acquires Orphai Therapeutics and Raises Up to $187 Million
Quince Therapeutics announced the acquisition of Orphai Therapeutics and a concurrent private placement to fund development of an inhaled rapamycin formulation for pulmonary diseases. The deal brings LAM-001 into Quince's pipeline and extends the company's cash runway through 202…
benzinga.comSilexion Therapeutics Reports First Quarter 2026 Financial Results
Silexion Therapeutics reported financial results for the three months ended March 31, 2026. The company also provided updates on regulatory approvals and planned clinical trials for its lead product candidate.
marketwatch.comDrugmaker Shares Fall After Skin Cancer Drug Trial Misses Target
Shares of an unnamed drugmaker fell in premarket trading after the company reported that a late-stage clinical trial of a skin cancer medication did not meet its primary goal. The announcement came before regular market hours.
ncbi.nlm.nih.govCAR-T Cell Therapy Shows Early Promise for Long-Term HIV Control
A small clinical trial tested CAR-T cell therapy in nine people with HIV. Two participants maintained undetectable virus levels for up to 20 months after stopping antiretroviral drugs.
theedgemarkets.comAntiviral Pill Cuts Household COVID-19 Infections in Trial
A five-day course of ensitrelvir reduced symptomatic COVID-19 cases among household contacts from 9 percent to 3 percent. The drug also lowered overall infection rates compared with placebo in a study of more than 2,000 people.
StatU.S. Officials Press Germany to Raise Drug Prices in Bid to Lower American Costs
U.S. officials told the German ambassador that Germany should pay more for pharmaceuticals as part of a broader effort to reduce prices paid in the United States. The meeting involved the U.S. Trade Representative and a senior health department adviser. Separately, some U.S. biot…
Fox NewsSmall University of Rochester Trial Finds Modest Cognitive Benefits From Exercise and Ibuprofen During Chemotherapy
A phase 2 trial of 86 cancer patients undergoing chemotherapy showed that a six-week home exercise program produced the clearest gains in attention and cognitive function. Low-dose ibuprofen alone also yielded greater cognitive improvements than placebo. Researchers cautioned tha…
Fox NewsPatient Reports Symptom Improvement in Phase III Trial of Experimental Targeted Chemotherapy for Pancreatic Cancer
Hernando Salcedo, 83, experienced fewer side effects and regained energy after eight TAMP sessions delivered via RenovoRx's RenovoCath device at Miami Cancer Institute. Early TIGeR-PaC trial data showed trends toward better survival and 65% fewer adverse events. Enrollment is exp…
StatBiogen Advances Tau-Targeting Alzheimer’s Drug to Phase 3 Despite Mixed Phase 2 Data
Biogen reported that its drug diranersen reduced tau levels in spinal fluid and brains of patients with early-stage Alzheimer’s in a Phase 2 trial. The reductions correlated with slower cognitive decline, though the study did not meet its primary efficacy goal of showing a dose r…
The IndependentUS Cancer Centers Report Surge in Requests for Experimental Pancreatic Cancer Drug
US cancer centers are seeing increased patient requests for daraxonrasib following positive clinical trial results that showed doubled survival rates for advanced pancreatic cancer. The FDA approved an expanded access program for the drug on 1 May, three weeks after the developer…
thestreet.comCompass Pathways Reports Positive Phase 3 Data for COMP360 in Treatment-Resistant Depression
Compass Pathways announced positive results from two Phase 3 trials of COMP360 for treatment-resistant depression during its first-quarter 2026 earnings call. The company has begun a rolling NDA submission with the FDA and received a Commissioner's National Priority Voucher. Offi…
japantimes.co.jpShionogi Antiviral Pill Cuts COVID-19 Infection Risk in Exposed Household Contacts
An experimental pill developed by Shionogi reduced the risk of COVID-19 infection among people exposed to the virus at home. The study marks the first time an antiviral pill has demonstrated preventive efficacy against SARS-CoV-2 in exposed individuals. Results were published in…
prnewswire.comEncoded Therapeutics Reports Initial Results from Gene Therapy Trial for Dravet Syndrome
A trial by Encoded Therapeutics involving 21 children with Dravet syndrome showed that sirolimus, used alongside steroids to prevent immune responses, could blunt the therapy's benefits. The findings, published May 13, 2026, come from a Boston-based report examining a key concern…
forbes.comOral Weight Loss Pill Orforglipron Helps Maintain Results After Injectable GLP-1 Drugs
Two randomized studies published in Nature Medicine show patients who switched from tirzepatide or semaglutide to daily oral orforglipron maintained 75 to 79 percent of their weight loss after one year, compared with 38 to 49 percent for those on placebo. The trial involved 376 p…
nypost.comOral Orforglipron Maintains Modest Weight Loss After Stopping Injectables, Trial Finds
A Nature Medicine study found that daily oral orforglipron allowed patients to retain most of their weight reduction after stopping tirzepatide or semaglutide injections. The trial of 376 U.S. participants showed significantly better maintenance than placebo. The drug, approved l…